Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloid Leukemia in Children with Down Syndrome 2018 (ML-DS 2018)
DRKS00023849Phase 3Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Mar 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, open-label trial of daunorubicin + cytarabine liposome, cytarabine, mitoxantrone, idarubicin and etoposide in acute myeloid leukemia (AML) (3 arms), sponsored by German Society for Pediatric Oncology and Hematology. Started Mar 2021; status: recruiting.
02
Drugs
daunorubicin + cytarabine liposomecytarabinemitoxantroneidarubicinetoposide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on DRKS00023849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00023849.